IVI in the Media

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

Her Majesty Queen Silvia of Sweden visits International Vaccine Institute on state visit

Author
ybcho
Date
2012-06-01 00:00
Views
6132
 
NEWS RELEASE
International Vaccine Institute
 
FOR IMMEDIATE RELEASE
2012-05-31  (KST)
 
Her Majesty Queen Silvia of Sweden visits International Vaccine Institute on state visit
 

-Her Majesty Queen Silvia of Sweden to visit and tour IVI facilities for the first time to see impact that IVI has around the globe
-Sweden was among the first signatory countries of IVI when the Institute was founded in 1997, and the Swedish International Development Cooperation Agency (Sida) has been a long-term donor to IVI since 2005
-Her Majesty has longstanding passion for charity, particularly in areas of disadvantaged children, as well as an international background

 

May 31, Seoul, South Korea- Her Majesty Queen Silvia of Sweden will visit the International Vaccine Institute (IVI) today as part of her and His Majesty King Carl XVI Gustaf of Sweden’s official state visit to South Korea. Through her first visit to the Institute’s headquarters based at Seoul National University, Her Majesty Queen Sylvia will participate in the IVI program that includes a luncheon, a tour of the IVI facilities and laboratories, and a presentation session that gives an overview of the impact that IVI is currently having in underdeveloped countries around the globe.

IVI Director General, Dr. Christian Loucq (right), greets Her Majesty Queen Silvia of Sweden, on her first visit to IVI headquarters.

Her Majesty Queen Silvia has been tirelessly involved in many charities, with a particular focus on disadvantaged children. Furthermore, Her Majesty Queen Silvia has a strong international background. She lived in Brazil where one of IVI's field sites is located, and speaks six languages including: Swedish, German, Portuguese, French, Spanish and English. Her Majesty’s passion for aiding disadvantaged children and her marked international spirit have rendered her an important partner for IVI.

 

"We are pleased to welcome Her Majesty Queen Silvia to IVI. Through our work in vaccines for the world's most vulnerable, IVI shares her humanitarian interest in ensuring the health and welfare of children around the world,” said IVI Director-General Dr. Christian Loucq. He added, "Our relationship with the government of Sweden has been longstanding and very significant to the fabric of IVI. We relish the opportunity to provide Her Majesty Queen Silvia with an interactive view of IVI, and we look forward to further cementing IVI’s partnership with Sweden."

Her Majesty Queen Silvia (second from right) of Sweden poses with IVI Director General, Dr. Christian Loucq (right); IVI Chairman of the Board of Trustees, Professor Ragnar Norrby (center); Professor Wan Kyoo Cho (second from left), Executive Advisor of the Korea Support Committee for IVI; and Ms. Maria Larsson (left), Minister for the Children and the Elderly, Ministry of Health and Social Affairs of Sweden.

Sweden is currently one of IVI's 41 signatories, and has been a supporter of the organization since its establishment in 1997. Sweden originally provided the technology for an oral cholera vaccine developed through IVI. It is the first vaccine from IVI's vaccine development portfolio to be brought to market and to be prequalified by the World Health Organization. IVI, in collaboration with partners in Sweden, Vietnam and India, specifically developed a low-cost, safe, and effective cholera vaccine to fight this deadly disease in developing countries. The vaccine is currently being introduced in cholera-ravaged settings in countries such as Haiti, India, and Bangladesh.

 

The Swedish International Development Cooperation Agency (Sida) has also been a key donor to IVI alongside the Korean Government and the Bill & Melinda Gates Foundation. Sida has provided support to many of the Institute's programs that include IVI's annual vaccinology course, now in its 12th year, that aims to strengthen the capacity of developing countries in the vaccine spectrum; typhoid surveillance studies in Africa; the development and publication of an investment case to support the global financing, stockpiling, and uptake of oral cholera vaccines; and the development of a new vaccine against typhoid fever and paratyphoid fever, two enteric diseases that affect many poorer countries.

Wearing tradiational Korean dress, or hanbok, children of IVI staff members greet Her Majesty Queen Silvia in IVI's lobby.


About IVI

The International Vaccine Institute (IVI) is the world's only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world's poorest people, especially children in developing countries. Established as an initiative of the United Nations Development Programme in 1997, IVI operates as an independent international organization under a treaty signed by 40 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int

 

 
IVI CONTACT : Tae Kyung Byun (Public Awareness / Advocacy Officer)
82-2-881-1159 Cellular: 011-9773-6071
IVI, SNU Research Park, San 4-8, Nakseongdae-dong, Gwanak-gu, Seoul, South Korea, 151-919
Phone: 82-2-872-2801, Cellular: 011-9773-6071, Fax: 82-2-872-2803 www.ivi.int e-mail: tkbyun@ivi.int
 
DONATE